tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
EyePoint Completes Enrollment for DURAVYU Phase 3 Trial
PremiumCompany AnnouncementsEyePoint Completes Enrollment for DURAVYU Phase 3 Trial
2M ago
EyePoint completes enrollment in Phase 3 LUGANO trial of DURAVYU
Premium
The Fly
EyePoint completes enrollment in Phase 3 LUGANO trial of DURAVYU
2M ago
EyePoint price target lowered to $26 from $30 at Mizuho
Premium
The Fly
EyePoint price target lowered to $26 from $30 at Mizuho
2M ago
EyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential
PremiumRatingsEyePoint Pharmaceuticals: Strong Buy Rating Backed by Promising Clinical Trial Progress and Market Potential
3M ago
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results
Premium
Company Announcements
EyePoint Pharmaceuticals Reports Q1 2025 Financial Results
3M ago
EyePoint reports Q1 EPS (65c), consensus (69c)
Premium
The Fly
EyePoint reports Q1 EPS (65c), consensus (69c)
3M ago
EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
PremiumCompany AnnouncementsEyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
5M ago
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Premium
Ratings
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating
5M ago
EyePoint Pharmaceuticals Reports 2024 Financial Results
Premium
Company Announcements
EyePoint Pharmaceuticals Reports 2024 Financial Results
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100